According to the World Health Organization (WHO), the number of people suffering from type 2 diabetes (T2D) is estimated at over 230 million. By 2025, this number is expected to reach over 300 million people worldwide.

In a majority of cases, the development of T2D is related to obesity.
According to the CDC, the US obesity population is over 35%, and this number is expected to cross the 50% by 2030.

For most of these patients, the only solution available today is drugs. For those with BMI>35 there is also an option of bariatric surgery.

Endobetix initial target is obese people (35>BMI>30) with T2D (total market estimated at 63 million worldwide).

All Rights reserved. Endobetix Ltd.